A clinical risk model predicts over 300 ILD-free days in urological cancer patients on immune checkpoint inhibitors

Japanese Journal of Clinical Oncology · Published 2026-07-20 · DOI 10.1093/jjco/hyag114

Authors (6)

Shinro Hata, Satoki Abe, Hiroyuki Fujinami, Yoshiyasu Sato, Naoyuki Yamanaka, Toshitaka Shin

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Hata, S., Abe, S., Fujinami, H., et al. (2026). A clinical risk model predicts over 300 ILD-free days in urological cancer patients on immune checkpoint inhibitors. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyag114

Related articles

• End-of-life cancer care quality in rural areas of Japan: an exploratory bereaved family survey · Japanese Journal of Clinical Oncology · 2026 · Same journal
• Developing quality indicators for supportive care in cancer treatment: a modified Delphi method · Japanese Journal of Clinical Oncology · 2026 · Same journal
• Hereditary cancer multigene panel testing in the United States and Europe: real-world constraints and implications for responsible integration in Japan · Japanese Journal of Clinical Oncology · 2026 · Same journal
• A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART) · Japanese Journal of Clinical Oncology · 2026 · Same journal
• Resolution of peritoneal metastases in CLDN18.2-positive gastric cancer treated with CAPOX plus zolbetuximab · Japanese Journal of Clinical Oncology · 2026 · Same journal
• Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study · Japanese Journal of Clinical Oncology · 2026 · Same journal
• Reconsidering prostate cancer screening: limitations of net survival and the primacy of overall survival as an endpoint · Japanese Journal of Clinical Oncology · 2026 · Same journal
• A multicenter randomized phase III trial of weekly cisplatin chemoradiotherapy versus radiotherapy in elderly patients with head and neck squamous cell carcinoma unfit for high-dose cisplatin: JCOG2405 (ELDER-WEEKLY) · Japanese Journal of Clinical Oncology · 2026 · Same journal
• Age-standardized mortality-to-incidence ratio for lymphoma in the world · Japanese Journal of Clinical Oncology · 2026 · Same journal
• Clinical utility of tumour markers in skeletal metastasis of unknown primary at the initial visit · Japanese Journal of Clinical Oncology · 2026 · Same journal